ストックスクリーナーアプリを入手
6.07
3.96%
-0.25
アフターアワーズ：
6.07
前日終値:
$6.32
開ける：
$6.41
24時間の取引高:
78,599
Relative Volume:
1.02
時価総額：
$102.75M
収益：
-
当期純損益:
$-12.36M
株価収益率:
-4.576
EPS:
-1.3265
ネットキャッシュフロー:
$-11.39M
1週間 パフォーマンス:
-17.19%
1か月 パフォーマンス:
-24.12%
6か月 パフォーマンス:
-30.47%
1年 パフォーマンス:
+13.46%
1日の値動き範囲:
$6.02
$6.74
1週間の範囲:
$6.02
$7.50
52週間の値動き範囲:
$4.75
$10.69
Coya Therapeutics Inc Stock (COYA) Company Profile
名前
Coya Therapeutics Inc
セクター
電話
650.739.3939
住所
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
COYA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| COYA | 6.07 | 102.75M | 0 | -12.36M | -11.39M | -1.3265 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Coya Therapeutics Inc (COYA) 最新ニュース
Trend Tracker for (COYA) - Stock Traders Daily
Insider Buying: CFO David Snyder Acquires Shares of Coya Therape - GuruFocus.com
Coya therapeutics CFO David Snyder buys $12,934 in stock - Investing.com
HC Wainwright Has Positive Forecast for COYA FY2024 Earnings - MarketBeat
Coya Therapeutics (NASDAQ:COYA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Coya Therapeutics (NASDAQ:COYA) Announces Earnings Results - MarketBeat
Meet 5 of the fastest-growing scaleup companies in Houston - InnovationMap
INNOVATIONMAP EMAILS ARE AWESOME - InnovationMap
Coya Therapeutics' (COYA) "Buy" Rating Reaffirmed at Chardan Capital - MarketBeat
Coya Therapeutics Reports Q3 2024 Highlights and Progress - TipRanks
Coya Therapeutics board member resigns due to new job policy By Investing.com - Investing.com Canada
Coya Therapeutics Advances Pipeline for Neurodegenerative Diseases - TipRanks
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results - The Bakersfield Californian
Coya Therapeutics board member resigns due to new job policy - Investing.com India
Long Term Trading Analysis for (COYA) - Stock Traders Daily
Arun Swaminathan assumes new role as chief executive officer of Coya Therapeutics - pharmabiz.com
Coya Therapeutics appoints new CEO amid Alzheimer's trial progress By Investing.com - Investing.com South Africa
Coya Therapeutics, Inc. (NASDAQ:COYA) Sees Significant Increase in Short Interest - MarketBeat
Coya Therapeutics appoints new CEO amid Alzheimer's trial progress - Investing.com
Coya Therapeutics Promotes Arun Swaminathan, Ph.D. to Chief Executive Officer - citybiz
Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer - StockTitan
Coya Therapeutics announces executive changes - Investing.com India
Coya Therapeutics Announces Leadership Change and New CEO - TipRanks
Coya Therapeutics announces executive changes By Investing.com - Investing.com UK
Coya Therapeutics On Developing A Combination Biologic - BioProcess Online
Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off (NASDAQ:COYA) - Seeking Alpha
Coya Therapeutics Reports Positive Phase 2 Alzheimer’s Trial Results - Yahoo Finance
Coya Therapeutics reports promising Alzheimer's trial results By Investing.com - Investing.com South Africa
See the Impacts of Waco’s Walk to End Alzheimer’s - AOL
Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study - Yahoo Finance
Coya stock tumbles 23% on mixed results from Alzheimer's study - MSN
Coya stock tumbles 23% on mixed results from Alzheimer's study (NASDAQ:COYA) - Seeking Alpha
Companies Like Coya Therapeutics (NASDAQ:COYA) Can Afford To Invest In Growth - Simply Wall St
Coya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trial - Reuters
Coya Therapeutics reports promising Alzheimer's trial results - Investing.com
Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer’s Disease - StockTitan
When (COYA) Moves Investors should Listen - Stock Traders Daily
Coya Therapeutics secures $10 million in private placement By Investing.com - Investing.com Australia
Coya Therapeutics Announces $10.0 Million Private Placement - citybiz
Coya Therapeutics Shares Rise 9% After $10 Million Private Placement - MarketWatch
Coya Therapeutics secures $10 million in private placement - Investing.com
Coya Therapeutics Announces $10M Private Placement to Advance Pipeline - TipRanks
Tips for preventing or delaying dementia - AOL
Coya Therapeutics Has Several Near-Term Share Price Appreciation Catalysts - Seeking Alpha
Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100 - citybiz
Exosomes Pipeline Dynamics 2024: FDA Approvals, Therapeutic - openPR
Exosomes Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, Latest FDA, EMA, and PMDA Approvals | Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, Endosome Therapy StemXO - Barchart
How the (COYA) price action is used to our Advantage - Stock Traders Daily
Coya Therapeutics Inc (COYA) 財務データ
収益
当期純利益
現金流量
EPS
3.66%
1.11%
大文字化:
|
ボリューム (24 時間):